Featuring a roundtable discussion with Drs Joshua Bauml, Nathan A Pennell and Lecia V Sequist. (Audio Program)
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Presenting Faculty Members
Joshua Bauml, MD
Assistant Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Consulting Agreements: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Guardant Health, Inivata, Janssen Biotech Inc, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Carevive Systems, Carisma Therapeutics, Clovis Oncology, Janssen Biotech Inc, Merck, Novartis, Takeda Oncology.
Nathan A Pennell, MD, PhD
Professor, Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Cleveland, Ohio
Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, COTA, G1 Therapeutics, Genentech, a member of the Roche Group, Inivata, Merck, Viosera Therapeutics, Xencor; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Lilly, Pfizer Inc.
Lecia V Sequist, MD, MPH
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital Cancer Center
The Landry Family Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.
Contributing General Medical Oncologists
Spencer Henick Bachow, MD
Hematologist/Oncologist at Lynn Cancer Institute
Affiliate Assistant Professor of Medicine at FAU Schmidt College of Medicine
Boca Raton, Florida
No relevant interests or affiliations to disclose.
Ranju Gupta, MD
Attending Physician
Co-Director, Cardio-Oncology Program
LVPG Hematology Oncology Associates
Lehigh Valley Health Network
Bethlehem, Pennsylvania
Speakers Bureau: Lilly.
Zanetta S Lamar, MD
Florida Cancer Specialists and Research Institute
Naples, Florida
No relevant interests or affiliations to disclose.
Namrata I Peswani, MD
Hematologist Oncologist
Harold C Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Richardson, Texas
No relevant conflicts of interest to disclose.
Syed Farhan Zafar, MD
Hematologist and Medical Oncologist
Florida Cancer Specialists and Research Institute
Chief, Division of Hematology and Oncology
Lee Health
Fort Myers, Florida
No relevant interests or affiliations to disclose.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Release date: May 2021
Expiration date: May 2022
(WIFI is recommended for best performance):